Quantitative assessment of the proliferative response of bronchoalveolar mononuclear cells to specific agents is a useful diagnostic test; a well-studied example is chronic beryllium disease.

Clinical molecularly targeted chemoprevention has surged forward since the late 1990s, with several targeted agents that prevent cancers, intraepithelial neoplasias and/or microbial infections ...